Reassessment: Gynecomastia as a Reversible Side Effect of Tamsulosin
-
August 18, 2026
Clinical Report: Gynecomastia as a Reversible Side Effect of Tamsulosin
Background
Gynecomastia is a condition that can occur as a side effect of medications like tamsulosin, which is commonly used for lower urinary tract symptoms associated with benign prostatic hyperplasia. Accurate classification of tamsulosin as an α1-adrenergic receptor antagonist rather than a 5α-reductase inhibitor is essential for guiding treatment decisions.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
- Tamsulosin is correctly classified as an α1-adrenergic receptor antagonist.
- The previous categorization of tamsulosin as a 5α-reductase inhibitor was incorrect.
- Gynecomastia may occur as a reversible side effect of tamsulosin.
- Guidelines primarily discuss gynecomastia in the context of 5-ARIs, not alpha-blockers like tamsulosin.
- Gynecomastia associated with 5-ARIs occurs in approximately 1-2% of patients, according to existing literature.
Clinical Implications
Clinicians should be aware of the potential for gynecomastia as a side effect of tamsulosin, although it is less commonly associated with this medication compared to 5-ARIs.
Conclusion
The reassessment of tamsulosin's classification and its side effects is vital for informed clinical practice.
Related Resources & Content
- Fiordellisi W, Schmidt GA, 2026 -- Reassessment: Gynecomastia as a Reversible Side Effect of Tamsulosin
- JAMA Network Open — Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men: A Randomized Clinical Trial
- Efficacy of 0.8 mg Tamsulosin in BPH Patients with Inadequate Response to 0.4 mg Monotherapy and Ineligibility for Surgery
- World Journal of Urology — Correlation between intravesical prostatic protrusion and ejaculatory dysfunction after tamsulosin treatment in men with BPH
- A fixed dose combination of tamsulosin and tadalafil in men with benign prostatic hyperplasia and erectile dysfunction: a prospective, multicenter, phase IV study
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management
- EAU Guidelines on the Management of Non-neurogenic Male LUTS - DISEASE MANAGEMENT
- https://www.nature.com/articles/s41598-025-20739-7.pdf
Based on findings from:
Correction: Tamsulosin-Induced Gynecomastia: Reversible Adverse Effect
Annals Of Internal Medicine: Clinical Cases, 2026.
https://www.acpjournals.org/doi/10.7326/aimcc.2026.0664
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
